spacer
home > ict > summer 2019 > post-marketing pharmacovigilance
PUBLICATIONS
International Clinical Trials

Post-Marketing Pharmacovigilance




European legislation requires that marketing authorisation holders (MAHs) should have an appropriate system for pharmacovigilance (PV) in place. Since the introduction of the updated legislation in July 2012, a set of guidelines for the conduct of PV has been developed by the EMA, known as good pharmacovigilance practice (GVP) modules, to support its implementation (1-4). Each GVP module covers one major PV process. The obligations are the same regardless of the MAH size or if the MAH is an innovative or a generic pharmaceutical company. However, the legislation and regulations do not stipulate how the MAH fulfils these obligations. It is up to the individual MAH to interpret the legislation and regulations and present, at audits and inspections, a system that complies with the requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the authors


Emma Boulton is the Head of Pharmacovigilance for UK and Ireland at Napp Pharmaceuticals. She has over 20 years of PV experience in both preand post-marketing. Emma is a serving committee member of PIPA and the Co-Chair of the PIPA training working party. Emma is a qualified nurse and holds a post-graduate diploma in Pharmacovigilance.



Dora Amene is the Pharmacovigilance Manager at TMC Pharma Services. She is a serving committee member of PIPA and Co-Editor for PIPA’s journal, which is published at least three times a year. Dora has a Master’s degree in Pharmacovigilance and seven years of PV experience in post-marketing and, recently, in clinical.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement